HRP conjugation with anti-SARS-CoV-2-nucleoprotein IgGs
Updated time: 2020-07-08 20:40:41
HRP conjugation with anti-SARS-CoV-2-nucleoprotein IgGs
Docket Number
28T-1090508
Announcement Date
2020-05-12
IP Status
know-how
Abstract
We assessed a general in vitro methodology based on phage-displayed synthetic antibody libraries in developing diverse antibodies against SARS-CoV-2 nucleoprotein. The anti-SARS-CoV-2 N protein IgGs with HRP conjugation can apply for basic scientific research and LFIA-based rapid detection tests.
Technological Advantages
- High affinity of HRP-conjugated IgGs against SARS-CoV-2 nucleoprotein
Applications of Technology
- Basic scientific research
- Rapid detection test
Inventor
An-Suei Yang
Contact person
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office
Download Files

HRP conjugation with anti-SARS-CoV-2-nucleoprotein IgGs